Non-steroidal Anti-inflammatory Drugs Market By Drug Type (Over-the-counter Drugs {Ibuprofen, ketoprofen, Aspirin, Naproxen, Others}, Prescription {Diclofenac, Celecoxib, Etodolac, Ketorolac, Indomethacin, Others}), By Indication (Pain Management {Acute Pain, Chronic Pain}, Inflammatory Conditions {Arthritis, Gout, Migraine}, Ophthalmic Diseases, Others), By Dosage Form (Tablets, Capsules, Creams, Ointments Injectable, Others), By Route of Administration (Oral, Parenteral, Topical), and By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & forecast parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Non-steroidal Anti-inflammatory Drugs Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. Rising Prevalence of Chronic Pain and Inflammatory Disorders Worldwide

3.2.2. Increasing Demand for Over-the-Counter NSAIDs in Emerging Markets

3.2.3. Growing Awareness About Pain Management and Accessibility of Medications

3.3. Key industry pitfalls & challenges

3.3.1. Adverse Effects Associated with Long-term Use of NSAIDs

3.3.2. Stringent Regulatory Policies Impacting Drug Approval and Marketing Processes

3.3.3. Competition from Alternative Therapies and Natural Pain Relief Options

3.4. Market Opportunities

3.4.1. Advancements in Drug Formulations for Improved Efficacy and Safety

3.4.2. Expansion of Distribution Channels in Underserved and Remote Regions

3.4.3. Growing Focus on Personalized Medicine and Targeted Drug Development

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Non-steroidal Anti-inflammatory Drugs Market, Drug Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Drug Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Over-the-counter Drugs

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.2. Ibuprofen

4.2.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.3. Ketoprofen

4.2.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.4. Aspirin

4.2.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.5. Naproxen

4.2.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.6. Others

4.2.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Prescription

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.2. Diclofenac

4.3.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.3. Celecoxib

4.3.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.4. Etodolac

4.3.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.5. Ketorolac

4.3.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.6. Indomethacin

4.3.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.7. Others

4.3.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Non-steroidal Anti-inflammatory Drugs Market, Indication Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Indication, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Pain Management

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.2.2. Acute Pain

5.2.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.2.3. Chronic Pain

5.2.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Inflammatory Conditions

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3.2. Arthritis

5.3.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3.3. Gout

5.3.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3.4. Migraine

5.3.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Ophthalmic Diseases

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5. Others

5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Non-steroidal Anti-inflammatory Drugs Market, Dosage Form Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Dosage Form, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Tablets

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Capsules

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Creams

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5. Ointments

6.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.6. Injectable

6.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.7. Others

6.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Non-steroidal Anti-inflammatory Drugs Market, Route of Administration Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By Route of Administration, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Oral

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Parenteral

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Topical

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Non-steroidal Anti-inflammatory Drugs Market, Distribution Channel Segment Analysis

8.1. Overview

8.1.1. Market Revenue Share, By Distribution Channel, 2025 & 2035

8.1.2. Key Market Trends, Growth Factors, & Opportunities

8.2. Hospital Pharmacy

8.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.3. Retail Pharmacy

8.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.4. Online Pharmacy

8.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

9. Non-steroidal Anti-inflammatory Drugs Market, Region Segment Analysis

9.1. Overview

9.1.1. Global Market Revenue Share, By Region, 2025 & 2035

9.1.2. Global Market Revenue, By Region, 2025-2035 (USD Billion)

9.2. North America

9.2.1. North America Market Revenue, By Country, 2025-2035 (USD Billion)

9.2.2. North America Market Revenue, By Drug Type, 2025-2035

9.2.3. North America Market Revenue, By Indication, 2025-2035

9.2.4. North America Market Revenue, By Dosage Form, 2025-2035

9.2.5. North America Market Revenue, By Route of Administration, 2025-2035

9.2.6. North America Market Revenue, By Distribution Channel, 2025-2035

9.2.7. The U.S.

9.2.7.1. U.S. Market Revenue, By Drug Type, 2025-2035

9.2.7.2. U.S. Market Revenue, By Indication, 2025-2035

9.2.7.3. U.S. Market Revenue, By Dosage Form, 2025-2035

9.2.7.4. U.S. Market Revenue, By Route of Administration, 2025-2035

9.2.7.5. U.S. Market Revenue, By Distribution Channel, 2025-2035

9.2.8. Canada

9.2.8.1. Canada Market Revenue, By Drug Type, 2025-2035

9.2.8.2. Canada Market Revenue, By Indication, 2025-2035

9.2.8.3. Canada Market Revenue, By Dosage Form, 2025-2035

9.2.8.4. Canada Market Revenue, By Route of Administration, 2025-2035

9.2.8.5. Canada Market Revenue, By Distribution Channel, 2025-2035

9.3. Europe

9.3.1. Europe Market Revenue, By Country, 2025-2035 (USD Billion)

9.3.2. Europe Market Revenue, By Drug Type, 2025-2035

9.3.3. Europe Market Revenue, By Indication, 2025-2035

9.3.4. Europe Market Revenue, By Dosage Form, 2025-2035

9.3.5. Europe Market Revenue, By Route of Administration, 2025-2035

9.3.6. Europe Market Revenue, By Distribution Channel, 2025-2035

9.3.7. Germany

9.3.7.1. Germany Market Revenue, By Drug Type, 2025-2035

9.3.7.2. Germany Market Revenue, By Indication, 2025-2035

9.3.7.3. Germany Market Revenue, By Dosage Form, 2025-2035

9.3.7.4. Germany Market Revenue, By Route of Administration, 2025-2035

9.3.7.5. Germany Market Revenue, By Distribution Channel, 2025-2035

9.3.8. France

9.3.8.1. France Market Revenue, By Drug Type, 2025-2035

9.3.8.2. France Market Revenue, By Indication, 2025-2035

9.3.8.3. France Market Revenue, By Dosage Form, 2025-2035

9.3.8.4. France Market Revenue, By Route of Administration, 2025-2035

9.3.8.5. France Market Revenue, By Distribution Channel, 2025-2035

9.3.9. U.K.

9.3.9.1. U.K. Market Revenue, By Drug Type, 2025-2035

9.3.9.2. U.K. Market Revenue, By Indication, 2025-2035

9.3.9.3. U.K. Market Revenue, By Dosage Form, 2025-2035

9.3.9.4. U.K. Market Revenue, By Route of Administration, 2025-2035

9.3.9.5. U.K. Market Revenue, By Distribution Channel, 2025-2035

9.3.10. Italy

9.3.10.1. Italy Market Revenue, By Drug Type, 2025-2035

9.3.10.2. Italy Market Revenue, By Indication, 2025-2035

9.3.10.3. Italy Market Revenue, By Dosage Form, 2025-2035

9.3.10.4. Italy Market Revenue, By Route of Administration, 2025-2035

9.3.10.5. Italy Market Revenue, By Distribution Channel, 2025-2035

9.3.11. Spain

9.3.11.1. Spain Market Revenue, By Drug Type, 2025-2035

9.3.11.2. Spain Market Revenue, By Indication, 2025-2035

9.3.11.3. Spain Market Revenue, By Dosage Form, 2025-2035

9.3.11.4. Spain Market Revenue, By Route of Administration, 2025-2035

9.3.11.5. Spain Market Revenue, By Distribution Channel, 2025-2035

9.3.12. Rest of Europe

9.3.12.1. Rest of Europe Market Revenue, By Drug Type, 2025-2035

9.3.12.2. Rest of Europe Market Revenue, By Indication, 2025-2035

9.3.12.3. Rest of Europe Market Revenue, By Dosage Form, 2025-2035

9.3.12.4. Rest of Europe Market Revenue, By Route of Administration, 2025-2035

9.3.12.5. Rest of Europe Market Revenue, By Distribution Channel, 2025-2035

9.4. Asia Pacific

9.4.1. Asia Pacific Market Revenue, By Country, 2025-2035 (USD Billion)

9.4.2. Asia Pacific Market Revenue, By Drug Type, 2025-2035

9.4.3. Asia Pacific Market Revenue, By Indication, 2025-2035

9.4.4. Asia Pacific Market Revenue, By Dosage Form, 2025-2035

9.4.5. Asia Pacific Market Revenue, By Route of Administration, 2025-2035

9.4.6. Asia Pacific Market Revenue, By Distribution Channel, 2025-2035

9.4.7. China

9.4.7.1. China Market Revenue, By Drug Type, 2025-2035

9.4.7.2. China Market Revenue, By Indication, 2025-2035

9.4.7.3. China Market Revenue, By Dosage Form, 2025-2035

9.4.7.4. China Market Revenue, By Route of Administration, 2025-2035

9.4.7.5. China Market Revenue, By Distribution Channel, 2025-2035

9.4.8. Japan

9.4.8.1. Japan Market Revenue, By Drug Type, 2025-2035

9.4.8.2. Japan Market Revenue, By Indication, 2025-2035

9.4.8.3. Japan Market Revenue, By Dosage Form, 2025-2035

9.4.8.4. Japan Market Revenue, By Route of Administration, 2025-2035

9.4.8.5. Japan Market Revenue, By Distribution Channel, 2025-2035

9.4.9. India

9.4.9.1. India Market Revenue, By Drug Type, 2025-2035

9.4.9.2. India Market Revenue, By Indication, 2025-2035

9.4.9.3. India Market Revenue, By Dosage Form, 2025-2035

9.4.9.4. India Market Revenue, By Route of Administration, 2025-2035

9.4.9.5. India Market Revenue, By Distribution Channel, 2025-2035

9.4.10. Australia

9.4.10.1. Australia Market Revenue, By Drug Type, 2025-2035

9.4.10.2. Australia Market Revenue, By Indication, 2025-2035

9.4.10.3. Australia Market Revenue, By Dosage Form, 2025-2035

9.4.10.4. Australia Market Revenue, By Route of Administration, 2025-2035

9.4.10.5. Australia Market Revenue, By Distribution Channel, 2025-2035

9.4.11. South Korea

9.4.11.1. South Korea Market Revenue, By Drug Type, 2025-2035

9.4.11.2. South Korea Market Revenue, By Indication, 2025-2035

9.4.11.3. South Korea Market Revenue, By Dosage Form, 2025-2035

9.4.11.4. South Korea Market Revenue, By Route of Administration, 2025-2035

9.4.11.5. South Korea Market Revenue, By Distribution Channel, 2025-2035

9.4.12. Singapore

9.4.12.1. Singapore Market Revenue, By Drug Type, 2025-2035

9.4.12.2. Singapore Market Revenue, By Indication, 2025-2035

9.4.12.3. Singapore Market Revenue, By Dosage Form, 2025-2035

9.4.12.4. Singapore Market Revenue, By Route of Administration, 2025-2035

9.4.12.5. Singapore Market Revenue, By Distribution Channel, 2025-2035

9.4.13. Rest of Asia Pacific

9.4.13.1. Rest of Asia Pacific Market Revenue, By Drug Type, 2025-2035

9.4.13.2. Rest of Asia Pacific Market Revenue, By Indication, 2025-2035

9.4.13.3. Rest of Asia Pacific Market Revenue, By Dosage Form, 2025-2035

9.4.13.4. Rest of Asia Pacific Market Revenue, By Route of Administration, 2025-2035

9.4.13.5. Rest of Asia Pacific Market Revenue, By Distribution Channel, 2025-2035

9.5. Latin America

9.5.1. Latin America Market Revenue, By Country, 2025-2035 (USD Billion)

9.5.2. Latin America Market Revenue, By Drug Type, 2025-2035

9.5.3. Latin America Market Revenue, By Indication, 2025-2035

9.5.4. Latin America Market Revenue, By Dosage Form, 2025-2035

9.5.5. Latin America Market Revenue, By Route of Administration, 2025-2035

9.5.6. Latin America Market Revenue, By Distribution Channel, 2025-2035

9.5.7. Brazil

9.5.7.1. Brazil Market Revenue, By Drug Type, 2025-2035

9.5.7.2. Brazil Market Revenue, By Indication, 2025-2035

9.5.7.3. Brazil Market Revenue, By Dosage Form, 2025-2035

9.5.7.4. Brazil Market Revenue, By Route of Administration, 2025-2035

9.5.7.5. Brazil Market Revenue, By Distribution Channel, 2025-2035

9.5.8. Argentina

9.5.8.1. Argentina Market Revenue, By Drug Type, 2025-2035

9.5.8.2. Argentina Market Revenue, By Indication, 2025-2035

9.5.8.3. Argentina Market Revenue, By Dosage Form, 2025-2035

9.5.8.4. Argentina Market Revenue, By Route of Administration, 2025-2035

9.5.8.5. Argentina Market Revenue, By Distribution Channel, 2025-2035

9.5.9. Mexico

9.5.9.1. Mexico Market Revenue, By Drug Type, 2025-2035

9.5.9.2. Mexico Market Revenue, By Indication, 2025-2035

9.5.9.3. Mexico Market Revenue, By Dosage Form, 2025-2035

9.5.9.4. Mexico Market Revenue, By Route of Administration, 2025-2035

9.5.9.5. Mexico Market Revenue, By Distribution Channel, 2025-2035

9.5.10. Rest of Latin America

9.5.10.1. Rest of Latin America Market Revenue, By Drug Type, 2025-2035

9.5.10.2. Rest of Latin America Revenue, By Indication, 2025-2035

9.5.10.3. Rest of Latin America Market Revenue, By Dosage Form, 2025-2035

9.5.10.4. Rest of Latin America Market Revenue, By Route of Administration, 2025-2035

9.5.10.5. Rest of Latin America Market Revenue, By Distribution Channel, 2025-2035

9.6. MEA

9.6.1. MEA Market Revenue, By Country, 2025-2035 (USD Billion)

9.6.2. MEA Market Revenue, By Drug Type, 2025-2035

9.6.3. MEA Market Revenue, By Indication, 2025-2035

9.6.4. MEA Market Revenue, By Dosage Form, 2025-2035

9.6.5. MEA Market Revenue, By Route of Administration, 2025-2035

9.6.6. MEA Market Revenue, By Distribution Channel, 2025-2035

9.6.7. GCC Countries

9.6.7.1. GCC Countries Market Revenue, By Drug Type, 2025-2035

9.6.7.2. GCC Countries Market Revenue, By Indication, 2025-2035

9.6.7.3. GCC Countries Market Revenue, By Dosage Form, 2025-2035

9.6.7.4. GCC Countries Market Revenue, By Route of Administration, 2025-2035

9.6.7.5. GCC Countries Market Revenue, By Distribution Channel, 2025-2035

9.6.8. South Africa

9.6.8.1. South Africa Market Revenue, By Drug Type, 2025-2035

9.6.8.2. South Africa Market Revenue, By Indication, 2025-2035

9.6.8.3. South Africa Market Revenue, By Dosage Form, 2025-2035

9.6.8.4. South Africa Market Revenue, By Route of Administration, 2025-2035

9.6.8.5. South Africa Market Revenue, By Distribution Channel, 2025-2035

9.6.9. Rest of Middle-East &Africa

9.6.9.1. Rest of Middle-East &Africa Market Revenue, By Drug Type, 2025-2035

9.6.9.2. Rest of Middle-East& Africa Market Revenue, By Indication, 2025-2035

9.6.9.3. Rest of Middle-East &Africa Market Revenue, ByDosage Form, 2025-2035

9.6.9.4. Rest of Middle-East&Africa Market Revenue, By Route of Administration, 2025-2035

9.6.9.5. Rest of Middle-East &Africa Market Revenue, By Distribution Channel, 2025-2035

10. Company Profile

10.1. Pfizer Inc.

10.1.1. Business Overview

10.1.2. Financial Performance

10.1.3. Drug/Service Offerings

10.1.4. Strategies & recent developments

10.1.5. SWOT Analysis

10.2. Johnson & Johnson

10.2.1. Business Overview

10.2.2. Financial Performance

10.2.3. Drug/Service Offerings

10.2.4. Strategies & recent developments

10.2.5. SWOT Analysis

10.3. Novartis AG

10.3.1. Business Overview

10.3.2. Financial Performance

10.3.3. Drug/Service Offerings

10.3.4. Strategies & recent developments

10.3.5. SWOT Analysis

10.4. Bayer AG

10.4.1. Business Overview

10.4.2. Financial Performance

10.4.3. Drug/Service Offerings

10.4.4. Strategies & recent developments

10.4.5. SWOT Analysis

10.5. AbbVie Inc.

10.5.1. Business Overview

10.5.2. Financial Performance

10.5.3. Drug/Service Offerings

10.5.4. Strategies & recent developments

10.5.5. SWOT Analysis

10.6. Merck & Co., Inc.

10.6.1. Business Overview

10.6.2. Financial Performance

10.6.3. Drug/Service Offerings

10.6.4. Strategies & recent developments

10.6.5. SWOT Analysis

10.7. GlaxoSmithKline plc (GSK)

10.7.1. Business Overview

10.7.2. Financial Performance

10.7.3. Drug/Service Offerings

10.7.4. Strategies & recent developments

10.7.5. SWOT Analysis

10.8. Sanofi

10.8.1. Business Overview

10.8.2. Financial Performance

10.8.3. Drug/Service Offerings

10.8.4. Strategies & recent developments

10.8.5. SWOT Analysis

10.9. Teva Pharmaceutical Industries Ltd.

10.9.1. Business Overview

10.9.2. Financial Performance

10.9.3. Drug/Service Offerings

10.9.4. Strategies & recent developments

10.9.5. SWOT Analysis

10.10. Horizon Therapeutics plc

10.10.1. Business Overview

10.10.2. Financial Performance

10.10.3. Drug/Service Offerings

10.10.4. Strategies & recent developments

10.10.5. SWOT Analysis

10.11. Perrigo Company plc

10.11.1. Business Overview

10.11.2. Financial Performance

10.11.3. Drug/Service Offerings

10.11.4. Strategies & recent developments

10.11.5. SWOT Analysis

10.12. Boehringer Ingelheim GmbH

10.12.1. Business Overview

10.12.2. Financial Performance

10.12.3. Drug/Service Offerings

10.12.4. Strategies & recent developments

10.12.5. SWOT Analysis

10.13. Sun Pharmaceutical Industries Ltd.

10.13.1. Business Overview

10.13.2. Financial Performance

10.13.3. Drug/Service Offerings

10.13.4. Strategies & recent developments

10.13.5. SWOT Analysis

10.14. Mylan N.V.

10.14.1. Business Overview

10.14.2. Financial Performance

10.14.3. Drug/Service Offerings

10.14.4. Strategies & recent developments

10.14.5. SWOT Analysis

10.15. Dr. Reddy’s Laboratories Ltd.

10.15.1. Business Overview

10.15.2. Financial Performance

10.15.3. Drug/Service Offerings

10.15.4. Strategies & recent developments

10.15.5. SWOT Analysis

10.16. Aurobindo Pharma

10.16.1. Business Overview

10.16.2. Financial Performance

10.16.3. Drug/Service Offerings

10.16.4. Strategies & recent developments

10.16.5. SWOT Analysis

10.17. Endo Pharmaceuticals Inc.

10.17.1. Business Overview

10.17.2. Financial Performance

10.17.3. Drug/Service Offerings

10.17.4. Strategies & recent developments

10.17.5. SWOT Analysis

10.18. Zydus Lifesciences Limited

10.18.1. Business Overview

10.18.2. Financial Performance

10.18.3. Drug/Service Offerings

10.18.4. Strategies & recent developments

10.18.5. SWOT Analysis